FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164266773> ?p ?o ?g. }

• W2164266773 endingPage "204" @default.
• W2164266773 startingPage "198" @default.
• W2164266773 abstract "Pulmonary inflammation is an important therapeutic target in cystic fibrosis (CF) patients, aiming to limit and delay the lung damage. The purpose of the present research was to produce respirable engineered particles of ketoprofen lysinate, a non-steroidal anti-inflammatory drug able to fight lung inflammatory status by direct administration to the site of action. Micronized drug powders containing leucine as dispersibility enhancer were prepared by co-spray drying the active compound and the excipient from water or hydro-alcoholic feeds. Microparticles were fully characterized in terms of process yield, particle size distribution, morphology and drug content. The ability of the drug to reach the deepest airways after aerosolization of spray-dried formulations was evaluated by Andersen cascade impactor, using the monodose DPI as device. In order to investigate the behaviour of the drug once in contact with lung fluid, an artificial CF mucus was prepared. Drug permeation properties were evaluated interposing the mucus layer between the drug and a synthetic membrane mounted in Franz-type diffusion cells. Finally, the effect of the engineered particles on vitality of human airway epithelial cells of patients homozygous for ΔF 508 CF (CuFi1) was studied and compared to that of raw active compound. Results indicated that powders engineering changed the diameter and shape of the particles, making them suitable for inhalation. The mucus layer in the donor compartment of vertical diffusion cells slowed down drug dissolution and permeation, leucine having no influence. Cell proliferation studies evidenced that the spray drying process together with the addition of leucine reduced the cytotoxic effect of ketoprofen lysine salt as raw material, making the ketoprofen lysinate DPI a very promising product for the inflammation control in CF patients." @default.
• W2164266773 created "2016-06-24" @default.
• W2164266773 creator A5005669717 @default.
• W2164266773 creator A5025363235 @default.
• W2164266773 creator A5051423176 @default.
• W2164266773 creator A5075775057 @default.
• W2164266773 creator A5089201408 @default.
• W2164266773 creator A5091102946 @default.
• W2164266773 date "2013-05-01" @default.
• W2164266773 modified "2023-10-14" @default.
• W2164266773 title "Non-steroidal anti-inflammatory drug for pulmonary administration: Design and investigation of ketoprofen lysinate fine dry powders" @default.
• W2164266773 cites W1533405076 @default.
• W2164266773 cites W1966242444 @default.
• W2164266773 cites W1975132504 @default.
• W2164266773 cites W1978062897 @default.
• W2164266773 cites W1978677166 @default.
• W2164266773 cites W1989694167 @default.
• W2164266773 cites W2000175714 @default.
• W2164266773 cites W2000619516 @default.
• W2164266773 cites W2014184580 @default.
• W2164266773 cites W2023325861 @default.
• W2164266773 cites W2030074619 @default.
• W2164266773 cites W2038033588 @default.
• W2164266773 cites W2054173689 @default.
• W2164266773 cites W2057496127 @default.
• W2164266773 cites W2060268703 @default.
• W2164266773 cites W2085051997 @default.
• W2164266773 cites W2097072748 @default.
• W2164266773 cites W2108043979 @default.
• W2164266773 cites W2118171734 @default.
• W2164266773 cites W2128123725 @default.
• W2164266773 cites W2133575035 @default.
• W2164266773 cites W2138058245 @default.
• W2164266773 cites W4236247973 @default.
• W2164266773 doi "https://doi.org/10.1016/j.ijpharm.2013.03.030" @default.
• W2164266773 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23528281" @default.
• W2164266773 hasPublicationYear "2013" @default.
• W2164266773 type Work @default.
• W2164266773 sameAs 2164266773 @default.
• W2164266773 citedByCount "32" @default.
• W2164266773 countsByYear W21642667732014 @default.
• W2164266773 countsByYear W21642667732015 @default.
• W2164266773 countsByYear W21642667732016 @default.
• W2164266773 countsByYear W21642667732017 @default.
• W2164266773 countsByYear W21642667732019 @default.
• W2164266773 countsByYear W21642667732020 @default.
• W2164266773 countsByYear W21642667732021 @default.
• W2164266773 countsByYear W21642667732022 @default.
• W2164266773 countsByYear W21642667732023 @default.
• W2164266773 crossrefType "journal-article" @default.
• W2164266773 hasAuthorship W2164266773A5005669717 @default.
• W2164266773 hasAuthorship W2164266773A5025363235 @default.
• W2164266773 hasAuthorship W2164266773A5051423176 @default.
• W2164266773 hasAuthorship W2164266773A5075775057 @default.
• W2164266773 hasAuthorship W2164266773A5089201408 @default.
• W2164266773 hasAuthorship W2164266773A5091102946 @default.
• W2164266773 hasConcept C105702510 @default.
• W2164266773 hasConcept C14029885 @default.
• W2164266773 hasConcept C178790620 @default.
• W2164266773 hasConcept C185592680 @default.
• W2164266773 hasConcept C18903297 @default.
• W2164266773 hasConcept C203014093 @default.
• W2164266773 hasConcept C2776042228 @default.
• W2164266773 hasConcept C2776954882 @default.
• W2164266773 hasConcept C2777239854 @default.
• W2164266773 hasConcept C2777312293 @default.
• W2164266773 hasConcept C2777419714 @default.
• W2164266773 hasConcept C2779587474 @default.
• W2164266773 hasConcept C2779820397 @default.
• W2164266773 hasConcept C2780035454 @default.
• W2164266773 hasConcept C2780261241 @default.
• W2164266773 hasConcept C2780744026 @default.
• W2164266773 hasConcept C2781430271 @default.
• W2164266773 hasConcept C41625074 @default.
• W2164266773 hasConcept C43617362 @default.
• W2164266773 hasConcept C50670333 @default.
• W2164266773 hasConcept C55493867 @default.
• W2164266773 hasConcept C71924100 @default.
• W2164266773 hasConcept C82085835 @default.
• W2164266773 hasConcept C86803240 @default.
• W2164266773 hasConcept C98274493 @default.
• W2164266773 hasConceptScore W2164266773C105702510 @default.
• W2164266773 hasConceptScore W2164266773C14029885 @default.
• W2164266773 hasConceptScore W2164266773C178790620 @default.
• W2164266773 hasConceptScore W2164266773C185592680 @default.
• W2164266773 hasConceptScore W2164266773C18903297 @default.
• W2164266773 hasConceptScore W2164266773C203014093 @default.
• W2164266773 hasConceptScore W2164266773C2776042228 @default.
• W2164266773 hasConceptScore W2164266773C2776954882 @default.
• W2164266773 hasConceptScore W2164266773C2777239854 @default.
• W2164266773 hasConceptScore W2164266773C2777312293 @default.
• W2164266773 hasConceptScore W2164266773C2777419714 @default.
• W2164266773 hasConceptScore W2164266773C2779587474 @default.
• W2164266773 hasConceptScore W2164266773C2779820397 @default.
• W2164266773 hasConceptScore W2164266773C2780035454 @default.
• W2164266773 hasConceptScore W2164266773C2780261241 @default.
• W2164266773 hasConceptScore W2164266773C2780744026 @default.
• W2164266773 hasConceptScore W2164266773C2781430271 @default.

• next